scholarly journals An Unusual Presentation of CLL/SLL on Mammography: Case Report

2020 ◽  
Author(s):  
Anas Mohamed ◽  
Ahmed Younes ◽  
John Stephen Stalls ◽  
Aisha Kousar ◽  
Tian Li
Keyword(s):  
Case Report ◽  
Chronic Lymphocytic Leukemia ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Contralateral Breast ◽  
Lymphocytic Leukemia ◽  
Small Lymphocytic Lymphoma ◽  
History Of

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) of the breast is rare. We report a 59-year-old female with remote history of ductal carcinoma in situ treated with radiation and tamoxifen, who was recently diagnosed with CLL/SLL of contralateral breast after a localized suspicious cluster of masses was detected on routine mammography.

scholarly journals Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Daniele Giardiello ◽  
Iris Kramer ◽  
Maartje J. Hooning ◽  
Michael Hauptmann ◽  
Esther H. Lips ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Systemic Therapy ◽  
Carcinoma In Situ ◽  
Contralateral Breast Cancer ◽  
Ductal Carcinoma ◽  
Contralateral Breast ◽  
Stage I ◽  
Adjuvant Systemic Therapy

Abstract We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). Women diagnosed with DCIS (N = 28,003) or stage I–III BC (N = 275,836) between 1989 and 2017 were identified from the nationwide Netherlands Cancer Registry. Cumulative incidences were estimated, accounting for competing risks, and hazard ratios (HRs) for metachronous invasive CBC. To evaluate effects of adjuvant systemic therapy and screening, separate analyses were performed for stage I BC without adjuvant systemic therapy and by mode of first BC detection. Multivariable models including clinico-pathological and treatment data were created to assess CBC risk prediction performance in DCIS patients. The 10-year cumulative incidence of invasive CBC was 4.8% for DCIS patients (CBC = 1334). Invasive CBC risk was higher in DCIS patients compared with invasive BC overall (HR = 1.10, 95% confidence interval (CI) = 1.04–1.17), and lower compared with stage I BC without adjuvant systemic therapy (HR = 0.87; 95% CI = 0.82–0.92). In patients diagnosed ≥2011, the HR for invasive CBC was 1.38 (95% CI = 1.35–1.68) after screen-detected DCIS compared with screen-detected invasive BC, and was 2.14 (95% CI = 1.46–3.13) when not screen-detected. The C-index was 0.52 (95% CI = 0.50–0.54) for invasive CBC prediction in DCIS patients. In conclusion, CBC risks are low overall. DCIS patients had a slightly higher risk of invasive CBC compared with invasive BC, likely explained by the risk-reducing effect of (neo)adjuvant systemic therapy among BC patients. For support of clinical decision making more information is needed to differentiate CBC risks among DCIS patients.

scholarly journals Modeling the natural history of ductal carcinoma in situ based on population data

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Sarocha Chootipongchaivat ◽  
Nicolien T. van Ravesteyn ◽  
Xiaoxue Li ◽  
Hui Huang ◽  
Harald Weedon-Fekjær ◽  
...  
Keyword(s):  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Data ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document